JP Morgan Maintains Overweight on Maze Therapeutics, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 71.2%

Neg 0% Neu 0% Pos 71.2%

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and raises the price target from $52 to $58.